INTERVIEW

Scohia Wants to Make Its “Carve Out” a Success Model for Japan Makers: CEO

April 5, 2017
As Takeda Pharmaceutical reworked its R&D strategies, the company pondered what to do with its renal, metabolic, and cardiovascular pipelines that might be promising but are no longer its core area. The answer was to split off eight ongoing projects…

To read the full story

Related Article

INTERVIEW

By Shinya Sato

As 2019 rolls in, we expect to see a flurry of approvals in the Japanese regenerative medicine arena, with regulatory decisions anticipated by the end of the year for Novartis Pharma’s CAR-T therapy and many more products, which could bring…

Takeda Pharmaceutical completed the £46 billion acquisition of Shire on January 8, vaulting itself into the top 10 league of…

By Gregory Ng

To many people, Japan has always been one of the world’s most advanced economies and a market of rich opportunities with one of the top healthcare systems worldwide.Add a rapidly changing demographic, a declining workforce, and the constant challenges of…

By Reiji Anasako

While generic drugs post solid growth in volume-based shares in Japan, their makers are pondering ways to retool their business…